Ames National Corp Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Ames National Corp acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 16,162 shares of the biopharmaceutical company’s stock, valued at approximately $429,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parsons Capital Management Inc. RI raised its holdings in Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares in the last quarter. Mcdonald Partners LLC grew its holdings in shares of Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in shares of Pfizer during the fourth quarter worth $264,000. Amplius Wealth Advisors LLC boosted its position in shares of Pfizer by 80.7% in the 4th quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock valued at $1,242,000 after purchasing an additional 20,911 shares during the period. Finally, Harvey Capital Management Inc. purchased a new position in Pfizer in the 4th quarter worth about $544,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Up 2.2%

NYSE PFE opened at $23.51 on Wednesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business has a fifty day moving average price of $23.56 and a two-hundred day moving average price of $25.27. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $133.66 billion, a PE ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. Pfizer’s dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.